Impact of multiple pathologies on the threshold for clinically overt dementia

2017/05/09 by Alifiya Kapasi, Charles DeCarli, Julie A. Schneider · 37 citations
Medicine · #Dementia and Cognitive Impairment Research #Alzheimer's disease research and treatments #Cerebrovascular and genetic disorders

paper · doi:10.1007/s00401-017-1717-7

Cited by

• Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
• The Revised National Alzheimer’s Coordinating Center’s Neuropathology Form—Available Data and New Analyses
• The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
• Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions
• Characterizing spatiotemporal white matter hyperintensity pathophysiology in vivo to disentangle vascular and neurodegenerative contributions
• Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
• Multimorbidity in dementia: Current perspectives and future challenges
• Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)
• 2026 Alzheimer's disease facts and figures
• Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
• 2023 Alzheimer's disease facts and figures
• 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
• The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. [europepmc]
• Person-specific contribution of neuropathologies to cognitive loss in old age. [europepmc]
• Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? [europepmc]
• Understanding the role of the perivascular space in cerebral small vessel disease. [europepmc]
• Tau Activates Transposable Elements in Alzheimer's Disease. [europepmc]
• Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. [europepmc]
• The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. [europepmc]
• Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. [europepmc]
• Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. [europepmc]
• White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. [europepmc]
• Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. [europepmc]
• Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. [europepmc]
• Preventing dementia by preventing stroke: The Berlin Manifesto. [europepmc]
• APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. [europepmc]
• Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. [europepmc]
• Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. [europepmc]
• Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. [europepmc]
• The development and convergence of co-pathologies in Alzheimer's disease. [europepmc]
• Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. [europepmc]
• Alzheimer disease. [europepmc]
• Neuropathology of Alzheimer's Disease. [europepmc]
• TDP-43 Pathology in Alzheimer's Disease. [europepmc]
• Genetics and Pathogenesis of Parkinson's Syndrome. [europepmc]
• Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. [europepmc]
• Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia. [europepmc]